S&P reaches highest level since February as Alphabet shares soar

AGCO Corp. (AGCO) Declares $0.15 Quarterly Dividend; 1% Yield

AGCO Corp. (NYSE: AGCO) declared a quarterly dividend of $0.15 per share, or $0.6 annualized.

The dividend will be payable on September 14, 2018, to stockholders of record on August 15, 2018, with an ex-dividend date of August 14, 2018.

The annual yield on the dividend is 1... More

Facebook (FB) PT Lowered to $200 at Piper Jaffray on Q2 Report; 'GDPR, Promotion of Stories & FX Drive Miss, Guide Down'

Piper Jaffray lowered its price target on Facebook (NASDAQ: FB) to $200.00 (from $250.00) while maintaining a Overweight rating, following the company's second quarter earnings report and cautious forward looking commentary from management.

Analyst Michael Olson notes a negative outlook on the shares, as FB management... More

Facebook (FB) PT Lowered to $195 at Baird on Q2 Report; 'Shares are Moving to the Penalty Box'

Baird lowered its price target on Facebook (NASDAQ: FB) to $195.00 (from $210.00) while maintaining a Outperform rating, following the company's second quarter earnings report.

Analyst Colin Sebastian notes a negative outlook on the shares, as FB management disclosed to investors "a significant... More

Needham & Company Reiterates Buy on Facebook (FB) Following In-Line 2Q

Needham & Company reiterated a Buy rating and $215.00 price target on Facebook (NASDAQ: FB) following the company's 2Q earnings report. FB reported 2Q18 revenue of $13.2B (up 42% y/y and 2% above Needham's estimate), Income from Operations of $5.9B (up 33% y/y and 2% below... More

Facebook (FB) PT Lowered to $140 at Pivotal Research Following 2Q

Pivotal Research lowered its price target on Facebook (NASDAQ: FB) to $140.00 (from $142.00) while maintaining a Sell rating following 2Q. Facebooks 2Q18 revenue was up by +42% with foreign exchange contributing $370mm, or nearly +3% of the figure. Reuters consensus called for +43% revenue growth and our... More

Facebook (FB) PT Lowered to $202 at Stifel Following 2Q

Stifel lowered its price target on Facebook (NASDAQ: FB) to $202.00 (from $242.00) while maintaining a Buy rating following the company's 2Q earnings report. Facebook reported 2Q total revenue growth of +42% y/y (to $13.2B, +38% y/ y ex-FX) below the Streets +43% y/y expectation. Ad revenue... More

Susquehanna Remains Bullish on Facebook (FB) Following 2Q

Susquehanna reiterated a Positive rating and $250.00 price target on Facebook (NASDAQ: FB) following the company's 2Q.

Reported revenue was ~1% below consensus, though it appears to have been negatively impacted by approximately two points from FX. EBITDA was modestly ahead by 1%.

For an... More

Facebook (FB) PT Lowered to $220 at Wells Fargo

Wells Fargo lowered its price target on Facebook (NASDAQ: FB) to $220.00 (from $250.00) while maintaining a Outperform rating following the company's 2Q earnings report. 2Q18 results missed the Street for the first time in 12 quarters, and CFO Wehner indicated that 3Q18 and 4Q18 revenue growth... More

Facebook (FB) PT Lowered to $225 at Credit Suisse Following 2Q

Credit Suisse lowered its price target on Facebook (NASDAQ: FB) to $225.00 (from $265.00) while maintaining a Outperform rating following the company's 2Q earnings report. FB reported revenues and Adjusted EPS of $13.2b/$2.11 vs consensus estimates of $13.3b/$2.01.

3Q18 estimates for revenues, adjusted EBITDA, and... More

Facebook (FB) PT Lowered to $190 at Macquarie Following 2Q Report

Macquarie lowered its price target on Facebook (NASDAQ: FB) to $190.00 (from $220.00) while maintaining a Outperform rating following the company's 2Q. Revenues and EPS were 4.2% and $0.07 below expectations, respectively. Analyst Benjamin Schachter thinks the headlines and selloff present a buying opportunity.

Schachter suspects concerns... More

Biogen (BIIB), Eisai Highlight Detailed Results from Phase II Clinical Study of Elenbecestat at AAIC 2018

Eisai Co., Ltd. and Biogen Inc. (NASDAQ: BIIB) announced detailed results from a Phase II clinical study (Study 202) of the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) at the Alzheimers Association International Conference (AAIC) 2018 being held in Chicago, Illinois, United States, from July 22 to 26, 2018. This poster presentation was accepted as a Late Breaking Abstract for AAIC (Poster No.: P4-389).

Study 202 (ClinicalTrials.gov identifier NCT02322021) is a multicenter, randomized, double-blind, placebo-controlled parallel-group 18-month Phase II clinical study, conducted in the United States in patients with... More

Alphabet (GOOGL) PT Raised to $1,425 at Aegis Capital

Aegis Capital raised its price target on Alphabet (NASDAQ: GOOGL) to $1,425.00 (from $1,360.00) while maintaining a Buy rating.